Skip to content



Carina Eldh

Chief Controlling Officer

In current position since 2019, employed since 2011.

Education: Secondary school economics 1989, graduate in accounting 1999, certified controller 2021.

Experience and prior assignments: Carina Eldh has more than 20 years of experience in accounting, auditing and taxation and has previously held positions at KPMG and other auditing and advisory firms, the Swedish Tax Agency and Öresundskraft.

Other current assignments: None

Born: 1970

Holdings: 9,900 shares.


Malin Hultqvist Hopkins


In current position since 2022.

Education: Master of Medicine in Pharmaceutical Bioscience, Gothenburg University, PhD in Medical Inflammation Research, Lund University.

Experience and prior assignments: Malin Hultqvist Hopkins has more than 15 years of experience in R&D and early drug discovery. She has held several operational roles at Redoxis AB, including Project Leader Drug Discovery, Director of CRO Studies and since 2016 she is the CEO of the company. Redoxis offers preclinical services. Malin holds a genuine experience in immunology and preclinical models of inflammation and autoimmunity.

Other current assignments: Board member of Redoxis AB and ProNoxis AB.

Born: 1979

Holdings: 7,950 shares through company.


Anneli Hällgren

Senior Consultant Preclinical Development

In current position since 2022.

Education: B.Sc. in Pharmacy and Ph.D. in Physiology from Uppsala University.

Experience and prior assignments: Anneli Hällgen has more than 25 years of experience from drug development with emphasis on nonclinical documentation for clinical trials and marketing applications within several therapeutic areas. Her career began at AstraZeneca, where she worked as a safety pharmacologist and preclinical project manager. Since then, she has held leading positions at companies such as KaroBio, Biolipox, Melacure Therapeutics and most recently she has worked as a consultant in preclinical drug discovery.

Other current assignments: None

Born: 1965

Holdings: 5,300 through company.


Martin Johansson

Chief Discovery Officer

In current position since 2019.

Education: Ph.D. in Organic Chemistry 2002, Associate Professor in Organic Chemistry 2007, and Master’s degree in Chemical Engineering 1997, Lund University.

Experience and prior assignments: Martin Johansson has been involved with Aqilion since 2012 as project manager for the former project company Glactone Pharma AB. He has 20 years of experience in medicinal chemistry and preclinical drug discovery and development. Previously, he has held the position of Chief Scientific Officer at Respiratorius AB and Senior Research Scientist at AstraZeneca, Discovery R&D.

Other current assignments: Board member of Selcis Biopharma AB.

Born: 1971

Holdings: 21,000 shares.


Anneli Tinnerholm


In current position since 2022.

Education: Bachelor of Medical Science in Medical Biology, Linköping University, studies in clinical drug development at Uppsala University.

Experience and prior assignments: Anneli Tinnerholm has more than 10 years of experience from clinical trials as Clinical Research Associate and Clinical Trial Project Manager. She has held several operational positions in the CRO companies NORMA and LINK Medical, followed by an advisory clinical project management role at SDS Life Science with focus on smaller pharma and biotech companies. Anneli has gained a broad competence within clinical operations from FIH (first in humans) and Phase I to Phase IV clinical trials in several indications and therapy areas.

Other current assignments:

Born: 1986

Holdings: 4,550 shares privately and through company.


Jan Törnell

Vice President Chief Medical Scientist

In current position since 2018.

Education: Medical degree, University of Gothenburg, 1985; Ph.D. in Physiology, Faculty of Medicine, Gothenburg, 1990; and Associate Professor in Physiology, 1992.

Experience and prior assignments: Jan Törnell has been involved with Aqilion/P.U.L.S. since 2012 through board positions in portfolio companies, as project manager/CEO and as an innovator. He also has many years of experience in executive positions in the pharmaceutical industry internationally. He has previously held the position of Global Vice President Strategy, Oncology & Infection and Global VP Translational Science at AstraZeneca and was Professor at the Department of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg.

Other current assignments: Chairman of the Board of Glactone Pharma AB, LIDDS AB (publ) and Innoext AB; Board member of Diaprost AB and Abliva AB (publ).

Born: 1960

Holdings: 7,644 shares.